one patient (Case 2) intramuscular nerve fibres could be seen enmeshed in fibrous tissue, this apparently causing superadded neurogenic muscular atrophy. The presence of discrete motor unit action-potentials on full volition suggests that the great-majority of the motor units in the muscle have degenerated leaving a few, relatively intact units. Why these should have been spared by the myopathic process is difficult to explain but this seems possible as normal outlines were seen in Cases 1, 2, 5 and 6, though in Cases 3 and 4 the potentials were highly polyphasic. The large amplitude of the action-potentials may be due to an electrical artifact, the amount of fibrosis decreasing the conductivity around the remaining motor units and thus increasing both amplitude and duration. It is known that fibrous tissue loses water as it ages and this again helps to explain why these findings occur in long-standing cases. The possible sequence of events therefore may be summarized as follows: progressive destruction of muscle-fibres with replacement by fibrous tissue; -fibrous tissue enmeshing motor nerve fibres thus completing the destruction of motor units; surviving motor units now in low volume-conductor giving large amplitude action-potentials.
These findings can thus cause a serious error in diagnosis. This error can probably be avoided by investigation early in the course of the disease and by searching a wide range of muscles, for the finding of a full interference pattern of disintegrated potentials (Fig 2) Chronic arthritis is a late manifestation of gout and is usually accompanied by tophaceous deposits. This stage is usually preceded by several years during which there are a number of acute episodes, but between these episodes there is freedom from joint symptoms. However, hyperuric*mia is persistent.
In addition to those who follow this classical pattern, one frequently sees patients suffering from chronic joint symptoms, with or without objective changes, who have hyperuricwnia but who do not give a history of episodes of acute arthritis.
The aim ofthis study was to investigate whether the raised serum uric acid, taken as an indication of raised 'total body urate pool', had any relationship to the joint symptoms.
Previous investigations of sulphinpyrazone by Yii et al. (1958) , Ogryzlo & Harrison (1957) and Kersley et al. (1958) have shown that it is a powerful, non-toxic and only feebly analgesic uricosuric agent, so that if patients in an otherwise steady state were given the drug, it would be seen whether the lowering of body urate content reduced joint changes.
Sulphinpyrazone (Anturan G.28315), a derivative of phenylbutazone, is the most powerful uricosuric agent available for general usage. A daily dose of 0 5 g is approximately as effective as 1 g of phenylbutazone, 3 g of probenecid or 6 g of aspirin (Ogryzlo & Harrison 1957) . It is rapidly and virtually completely absorbed from the intestine and is rapidly metabolized with a half-life of three hours (Burns et al. 1957) . Optimal administration is therefore six-hourly; 100 mg q.d.s. has been shown to be adequate in most cases (Yu et al. 1958 ).
Criteria for admission of patients to the trial were: (1) Chronic joint symptoms inadequately relieved by routine analgesics and physiotherapy.
(2) Serum uric acid repeatedly raised above 6-0 mg/100 ml in a male or 5-5 mg/100 ml in a female.
(3) Absence of evidence of blood, renal, parathyroid or cardiac disease.
A controlled trial was intended, but was not found to be possible. Patients were all observed for a period before therapy was started and then seen monthly.
Treatment
Sulphinpyrazone 100 mg q.d.s. was given for periods of four to twelve months. No physiotherapy was given and the patients were told to avoid aspirin or similar preparations as these interfere with the uricosuric action of sulphinpyrazone (Kersley et al. 1958) . A supply of paracetamol tablets was given for casual pain relief and phenylbutazone for any marked joint symptoms. Paracetamol has no uricosuric action itself (Batterman & Grossman 1955) and does not interfere with the ac.ion of sulphinpyrazone (Seegmiller & Grayzel 1960) .
Monthly assessment (a) Joint symptoms: The extent of subjective joint involvement was recorded by the 'Distribution Index' suggested by Lansbury & Haut (1956) . (b) Objectivejoint change: Alljoints were examined for swelling, stiffness, limitation of and pain on movement. The circumferences of knee (tapemeasure) and finger (jewellers' rings) joints were recorded. Grip strength was measured on an inflatable balloon. A second, objective, 'Distribution Index' was estimated. (c) Blood and urine: Hlemoglobin, platelet count, total and differential white cell count, sedimentation rate, blood urea and serum uric acid were estimated. Urine was examined for protein and microscopically.
Cases (Table 1) Ten patients started the trial and 9 continued treatment. Two had residual symnptoms after acute gouty arthritis but no evidence of tophi. Two satisfied the American Rheumatism Association criteria for 'definite' rheumatoid arthritis and had positive Rose tests. One had gross degenerative arthritis of her knees and the other 5 had indeterminate joint changes with normal X-rays and blood sedimentation rates, negative Rose tests, hyperuricaemia, but no history of acute arthritis and no tophi. Two of these 5 had positive family histories of gout. Only 2 were females and their ages were 69 and 72.
Results
The serum uric acid was lowered to normal limits in all cases ( Table 2 ). The average fall was to 61 % of the previous values with a variation of 40-84 %/s. The average figure before treatment was 6-7 mg% and during treatment 4'2 mg%.
In no case did the blood urea rise. In 6 cases it remained stationary and in 3 (R T, A H, & T E) it fell 10 mg/100 ml. The blood sedimentation rate was not altered. Within a few weeks of starting uricosuric therapy, 2 patients, (W M & S E) experienced dramatic relief of joint symptoms. A similar response was found by Yu et al. (1958) in 3 of 8 cases with chronic joint pain and stiffness. It is of interest that one (S E) experienced an even more dramatic alleviation of migraine. Six patients experienced gradual but definite improveement with one-third to total relief of symptoms (Table 4 ). The patient with gross osteo-arthritic knees (A S) derived no benefit.
The two best results were in cases with very good lowering of the serum uric acid level and the failure was in the case showing least urate response.
The patients receiving most benefit were the 2 with a family history of gout and they both had previously derived partial benefit from colchicine.
No uniform systemn of objective grading could be used because of the diverse nature of the patients' signs and symptoms (Tables 3 & 4) . (1) Grip strength: Of 6 cases with hand involvement, definite improvemnent occurred in 4. There was no change in 2.
(2) Joint circumferences: Five patients had knee involvement. In 3 the series of monthly measurements showed a consistent trend with reductions of 4, -and 9 in. in the average figures during treatment. No change was observed in 2 cases.
Two patients had enlarged interphalangeal joints. The series of measurements with jewellers' rings, showed a small but consistent reduction in size.
(3) Recordings of the number ofjoints considered abnormal at examination were usually inconsistent although they did show significant improvement in 4 cases. Function tests involving walking and manual dexterity were not helpful as 9 of the 10 patients were fully active.
Follow-up
Seven cases were followed up for periods of four to fourteen months after finishing treatment. The serum uric acid rose again in all 7 (Table 2) . During the follow-up, 3 (B P, A H & L W) maintained their imnprovement. Two (S E & F W) experienced a slight return of symptoms. One (R 1) remnained symptom free for four months and then had a mild relapse. After a year he had a more severe relapse of symptoms despite taking phenylbutazone, and sulphinpyrazone has been restarted. A S remained unchanged.
Side-effects
One patient (J S) developed severe diarrhlea on two separate occasions when he started taking sulphinpyrazone and so had to be withdrawn from the trial. One patient experienced mild dyspepsia after he had been on sulphinpyrazone for four months. The drug was stopped for ten days and then restarted. The dyspepsia gradually cleared.
One patient (R T) complained of impotence starting during therapy but continuing a year after stopping the drug. He was very anxious and psychogenic factors were probably responsible. No other side-effects were found.
In the largest reported series of cases (44 patients), treated by sulphinpyrazone (YOi et al. 1958) , 5 developed dyspepsia soon after starting, and 2 had to stop treatment. Eight patients experienced renal colic. UJrate crystals were seen once without symptoms. They also reported that 1 patient developed leucopmenia.
Since sulphinpyrazone is a derivative of phenylbutazone, evidence of bone-marrow depression was carefully sought in our study. In 3 of the cases the white cell count fell slightly on starting sulphinpyrazone. In W M it fell from 6,000 to 4,000, but recovered to 8,000 the following month. In S E it fell from 8,000 to 7,000 during four months' treatment and subsequently fell to 6,000 during the follow-up period. In the third patient AS the count dropped from 8,000 to 5,000 during the first month of therapy and gradually rose to 6,000 during the following year.
No effect on platelets was observed, but in four cases a 10% drop in heinoglobin was found during treatment with recovery afterwards. No blood changes have been reported in any other series.
The most commonly reported harmful effect of treatment with sulphinpyrazone is precipitation of acute attacks of gout. This occurred in 5 of the 44 cases of Yu et al. (1958) and 9 of the 13 cases of Kersley et al. (1958) despite the simultaneous administration of colchicine. Roden (1960) found this complication in 2 of 5 patients treated. (No similar episode occurred in our series; only the first 2 patients were given colchicine.) No other side-effects were recorded in the above three series, the 11 patients treated by Ogryzlo & Harrison (1957) , or the 17 patients of Smyth et al. (1960) . Skin rashes have apparently occurred in patients treated by sulphinpyrazone, but not in the 105 patients reviewed here.
Our series therefore confirms the low incidence of side-effects with sulphinpyrazone; even lower than the 5 % gastric and 8 % renal complications with probenecid, but probably a higher tendency to precipitate acute attacks than the 10% incidence with probenecid reported by Gutman & Yu (1957) reviewing 169 cases.
Discussion
The pathogenesis of the acute episodes of gout is still not known but is probably quite different from the cause of the chronic joint symptoms in tophaceous gout. In the latter condition, it is probably the deposition of urates in and around the joints that leads to pain and stiffness. If two different mnechanisms are involved, there should be cases who have had hyperuricLemia for years and although they have escaped any acute gouty episodes, they have nevertheless an increased body urate content with diffuse deposits in or around some of their joints, even in the absence of macroscopic collections of urates, demonstrable as tophi. Such diffuse deposits of urates, therefore, could be the cause of joint changes in patients with chronic hyperuricxemia without a history of acute gouty arthritis. If so, the obvious treatment would be uricosuric therapy.
The fact that the patients in this series derived benefit from a non-analgesic uricosuric agent suggests that their symptoms were due to urate deposits, which were mobilized and excreted as a result oftreatment.
Conclusion
This study suggests that uricosuric therapy may be of value in cases other than chronic tophaceous gout and that further studies of the relationship between hyperuricemia and joint changes should be performed. It confirms that sulphinpyrazone is an effective and safe uricosuric agent.
